SCHEMBL2901113

SCHEMBL2901113

COc1cnc(-n2c(=S)[nH]c3cc(C(=O)NCc4cccc(C(=O)c5ccccc5)c4)ccc3c2=O)nc1OC

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 8/20 0.54
▸ KMT2A Q03164 8/20 0.54
▸ ALDH1A1 P00352 8/20 0.52
▸ MAPT P10636 5/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ USP2 O75604 1/20 0.50
▸ LMNA P02545 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ RXFP1 Q9HBX9 2/20 0.46
▸ TP53 P04637 2/20 0.46
▸ TSHR P16473 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ EGLN3 Q9H6Z9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2903498 0.95 USP2 (0.56) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL2901148 0.90 KMT2A (0.55) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL2919143 0.87 THRB (0.53) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL2897948 0.87 MEN1 (0.70) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL2913829 0.87 KMT2A (0.57) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL2902346 0.86 KMT2A (0.58) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL2895179 0.86 EGLN3 (0.57) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL2903505 0.85 MEN1 (0.52) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL2914566 0.85 KMT2A (0.49) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL13037502 0.83 ALDH1A1 (0.48) MEN1KMT2AALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US claimed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 — — EP claimed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO claimed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 MEN1 4104/4885KMT2A 395/4885ALDH1A1 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback